Skip to main content
Sign In
 

Daniel Chan, PhD

Professor, Division of Medical Oncology


 Dan Chan Photo

Education: PhD

University of Hawaii at Manoa, Honolulu, HI 
MSc 1974, PhD 1979

 

Dr. Chan joined the faculty of the Division of Medical Oncology in 1988 as an instructor. Before coming to University of Colorado Denver, Dr. Chan trained at the Cancer Research Center of Hawaii as a Junior Researcher and as an Assistant Research Professor after obtaining his PhD at the University of Hawaii at Manoa. He also trained as a postdoctoral fellow at the Center of Nuclear Studies in Grenoble, France. 

Research
Dr. Chan’s research focus is in Lung Cancer. He has contributed richly in the field of Lung Cancer Research. Some of his accomplishments include registering over 8 patents with several pending and being awarded the 2006 School of Medicine Ph.D. Research and Teaching Award.

Publications
(selected from 95 peer-reviewed publications)

1.     Brechbuhl, Heather, Kachadourian R, Min E, Chan, D, and Day, BJ. Chrysin enhances doxorubicin-induced cytotoxicity in several human lung epithelial cancer cell lines: the role of glutathione. Toxicology an Applied Pharmacology, 258: 1-9, 2012
 
2.     Mara Gladstone, Barbara Frederick, Di Zheng, Anthony Edwards, Petros Yoon, Stefanie Stickel, Tessie DeLaney, Daniel C Chan, David Raben, and Tin Tin Su: A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer.  Disease Model and Mechanism 5: 342-350, 2012.
 
3.     Matias Casas Selves, Jihye Kim, Yhiyong Zhang, Barbara Helfrich, Dexiang Gao, Christopher C. Porter, Paul Bunn, Daniel Chan, Aik Choon Tan, James DeGregori: Tankyrase and the Canonical Wnt pathway protect lung cancer cells from EGFR inhibition.  Cancer Research, 72: 1-11, 2012.
 
4.     Samiha Mateen, Komal Raina, Anil Jain, Chapla Agarwal, Daniel Chan, Rajesh Agarwal: Epigenetic modifications and p21-cyclin B1 nexus in anti-cancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.  Epigenetics 7(10): 1161-1172, 2012.
 
5.     Samiha Mateen, Komal Raina, Chapla, Agarwal, Daniel Chan and Rajesh Agarwal: Silibinin synergizes with histone deacetylase and DNA methytransferase inhibitiors in up-regulating E-Cadherin expression in non-small cell lung cancer cells.  J Pharmacology and Experimental Therapeutics, 2013, JPET Fast Forward. Published on March 5, 2013 as DOI:10.1124/jpet.113.203471
 
6.     Charu Gupta, Girish Sharma and Daniel Chan: “Resveratrol: a chemopreventative agent with diverse applications” in Phytochemicals of Nutraceutical Importance, Editors: Dhan Prakash and Girish Sharma, Chapter 4, p. 47-60, CABI Publisher (2013).
 
7.     Jingjing Gong, Amanda R Muñoz, Daniel Chan, Rita Ghosh and Addanki P Kumar: Stat3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth, Oncotarget 5: 1-13, 2014
 
8.     Terry Moody, Daniel Chan, Samuel A Mantey, Paola Moreno, and  Robert T Jensen:  SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner. Life Sciences 100(1) 25-34, 2014. 
 
 

Funding

Source:                         NIH-RO1
Time:                            July 2011 to June 2016 (funded)
PI:                                James DeGregori, Co-PI: Dan Chan, PhD
Title:                             Rationally designed targeted therapeutic approaches for NSCLC
Annual direct cost        $365,540
 
Source:                        Merrimack Pharmceuticals
Time:                            May 2012 – May 2016 (funded)
PI:                                Dan Chan, PhD
Title:                             In vivo studies of MM398 (liposomal irinotecan), liposomal taxanes and MM-121(bispecific antibodies) for lung cancer
Annual direct cost        $150,000
 
Source:                         Amgen
Time:                            Jan 2013 to Jan 2015 (Funded)
PI:                                 Dan Chan, PhD
Title:                              In vivo studies of Anti-RunkL antidbodies for lung cancer
Annual Direct cost        $275,000 (for Dan Chan portion)
 
Source:                         PharmaEngine, Inc
Time:                            March, 2013 to Mar 2015 (funded)
PI:                                 Dan Chan, PhD
Title:                             PEP503 (hafnium oxide) for enhanced radiotherapy
Annual Direct Cost       $180,000
 
Source                         Georgia Institute of Technology
Time:                            Feb 22, 2014 to Jan 21, 2015 (funded)
PI:                                 Dan Chan, PhD
Title:                             GIT Non-peptide HDAC inhibitor for lung cancer therapy
Annual Direct cost        $23,564
 
University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.